Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health Azelaic Acid Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG059

    Azelaic acid 15% gel

    Customize your policy alerts

    Sign up for Oscar Health Policy PG059 alerts

    Get alerted when Policy PG059 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs prior authorization and medical-necessity review for azelaic acid 15% gel for inflammatory papules and pustules associated with mild-to-moderate papulopustular rosacea, subject to the stated clinical criteria.

    Policy Summary
    PayerOscar Health
    PolicyAzelaic acid 15% gel
    Policy CodePolicy PG059
    Change TypeNo material change
    Effective DateN/A
    Last ReviewAug 3, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming the member is at least 18 years old, has mild-to-moderate papulopustular rosacea, and cannot use or has adequately tried and failed topical metronidazole for at least one month.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum member age
    1 monthMetronidazole trial
    36 monthsMaximum approval duration
    Mild-to-moderateCovered rosacea severity
    PapulopustularCovered rosacea type

    Azelaic Acid 15% Gel Coverage Criteria

    Azelaic acid 15% gel for papulopustular rosacea

    Covered when ALL of the following criteria are met:

    Rosacea medical-necessity criteria

    • Member age: The member is 18 years of age or older.18 years or older
    • Clinical indication: The member is using the requested medication for the treatment of inflammatory papules and pustules of mild-to-moderate rosacea (i.e., papulopustular rosacea).Mild-to-moderate papulopustular rosacea with inflammatory papules and pustules
    • Prior topical metronidazole therapy:
    Policy Summary
    PayerOscar Health
    PolicyAzelaic acid 15% gel
    Policy CodePolicy PG059
    Change TypeNo material change
    Effective DateN/A
    Last ReviewAug 3, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming the member is at least 18 years old, has mild-to-moderate papulopustular rosacea, and cannot use or has adequately tried and failed topical metronidazole for at least one month.
    SourceLink
    On This Page
    Azelaic Acid 15% Gel Coverage CriteriaDocumentation and Authorization RequirementsClinical BackgroundKey Clinical Terms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    The member is unable to use, or has adequately tried and failed, topical metronidazole for a minimum one-month trial.
    Minimum 1 month

    This criterion is subject to a state-mandate indicator.

    Use of azelaic acid 15% gel for any indication other than treatment of inflammatory papules and pustules associated with mild-to-moderate papulopustular rosacea is not covered and is considered experimental, investigational, or unproven.

    Documentation and Authorization Requirements

    Documentation Required

    Document Rosacea Criteria

    Document that the member meets all clinical criteria for azelaic acid 15% gel: age 18 or older, a diagnosis of mild to moderate papulopustular rosacea with inflammatory papules and pustules, and the required topical metronidazole history.

    • Member is 18 years of age or older.
    • Requested medication is for inflammatory papules and pustules of mild to moderate rosacea (papulopustular rosacea).
    • Document whether the member is unable to use topical metronidazole or has adequately tried and failed it for the required minimum duration.
    Step Therapy

    Topical Metronidazole Prerequisite

    Before requesting azelaic acid 15% gel, document that the member is unable to use topical metronidazole or has adequately tried and failed topical metronidazole for a minimum one-month trial.

    • Required prerequisite: inability to use topical metronidazole, or an adequate trial and failure of topical metronidazole.
    • Minimum trial duration: one month.
    Denial Risk

    Clinical Criteria Not Met

    Coverage criteria are not met when the member is under age 18, the requested medication is not being used to treat mild to moderate papulopustular rosacea with inflammatory papules and pustules, or the topical metronidazole prerequisite is not satisfied and documented.

    • Deny when the member is under 18 years of age.
    • Deny when the indication is not mild to moderate papulopustular rosacea with inflammatory papules and pustules.
    • Deny when the member can use topical metronidazole and has not adequately tried and failed it for a minimum one-month trial.
    Denial Risk

    Other Indications Unproven

    Azelaic acid 15% gel for any indication other than the specified treatment of mild to moderate papulopustular rosacea is considered experimental, investigational, or unproven.

    • Other indications are experimental, investigational, or unproven.

    Clinical Background

    Rosacea is a skin condition that primarily affects the face. It may cause redness, swelling, inflammation, papules, pustules, visible dilated blood vessels, and rhinophyma. Management may include trigger avoidance, gentle skin care, sun protection, laser or light therapy, topical agents, and oral antibiotics. Topical metronidazole and azelaic acid gel are described as first-line treatments for mild-to-moderate disease with inflammatory papules and pustules.

    Key Clinical Terms

    Papule
    DefinitionA raised area of the skin, usually pink or red, that occurs in conditions such as rosacea and dermatitis.
    Pustule
    DefinitionA bump on the skin that contains pus or liquid.
    Rosacea
    DefinitionA skin condition primarily affecting the face that can present as redness, swelling, inflammation that includes papules and pustules, dilated blood vessels that appear on the surface of the skin, and rhinophyma, characterized by an enlarged, red nose.